FDA mulls behind-the-counter drug sales

Once, the gap between prescription drugs and over-the-counter sales was a wide No Man's Land where few products roamed. Now, the FDA may settle more medications in this country, known as behind-the-counter (BTC) sales, in part to improve access for the uninsured.

The agency is seeking public comment on the potential move, which would allow patients to buy certain remedies after consultation with a pharmacist. Though the FDA won't cite specific meds that might be included, experts cite birth control pills and cholesterol-lowering remedies as possibilities.

- see the AP article

Related Articles:
House overhauls, passes PDUFA. Report
FDA clears Plan B, ending FDA confirmation fight. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.